Home > Insider Trading > Filing (0001140361-13-001849)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1023869	Merilee Raines	One Idexx Drive Westbrook ME 04092	Executive Vp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-01-09	2,032	$38.34	148,053	No	4	M	Direct
Common Stock	Acquisiton	2013-01-09	5,694	$17.14	153,747	No	4	M	Direct
Common Stock	Disposition	2013-01-09	3,226	$97.51	150,521	No	4	S	Direct
Common Stock	Disposition	2013-01-09	4,500	$96.92	146,021	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2013-01-09	2,032	$0.00	2,032	$38.34
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2013-01-09	5,694	$0.00	5,694	$17.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2013-02-13	No	4	M	Direct
0		2013-02-06	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,430	Indirect	By Charitable Remainder Trust

Footnotes

The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/26/2012.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $97.27 to $97.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $96.27 to $97.26, inclusive.
Grant of options to buy shares of common stock becomes exercisable as to 2,960 shares on 02/14/2007, 02/14/2008, 02/14/2009, 02/14/2010, and the remaining 352 shares on 02/14/2011.
Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, 02/06/2007, and the remaining 2,164 shares on 02/06/2008.